Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/605367


XTENT, Inc. Product Pipeline Analysis


Description: XTENT, Inc. Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Scope’s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

- Details of development stage by sector and equipment type.
- Pipeline products grouped by therapy area, development stage and trial phase.
- Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
- Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
- Product updates covering estimated approval dates and estimated launch dates.
- Descriptions of novel technologies relating to pipeline products of the company.
- Patents and patent applications covered for the product.
- News updates on key events relating to the product and its development.

Reasons to buy

- A single source to fulfill competitor information relating to products in development.
- Identify pipeline products that are potential competitor to your product lines.
- Understand a companys strategic position by accessing detailed independent intelligence on its product pipeline.
- Access clinical trial information to map trial results and plan targeted marketing activities.
- Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
- Identification of potential investment opportunities.
- Build up knowledge base for potential distribution and marketing partners.
- Helps avoid patent infringement.
- Timelines from concept to market lets you keep track of market potential build for a new product.
- Assess a companys future growth by determining its pipeline depth, for probable acquisition opportunities.


Contents: 1 2
1.1 List Of Tables 5
1.2 List of Figures 6
2 Company Overview 7
2.1 Key Information 7
2.2 Financial Performance 7
2.3 Industry Outlook - Cardiovascular Devices 7
3 XTENT, Inc. Pipeline Products 8
3.1 XTENT, Inc. Product Pipeline Analysis 8
3.1.1 XTENT, Inc. Pipeline Products By Equipment Type 8
3.1.2 XTENT, Inc. Pipeline Products By Development Stage 8
3.1.3 XTENT, Inc. Pipeline Products By Therapy Area 8
3.1.4 XTENT, Inc. Pipeline Products By Clinical Trials 9
3.1.5 XTENT, Inc. Pipeline Products By News Summary 10
3.2 Custom NX 60 11
3.2.1 Product Status 11
3.2.2 Product Description 11
3.2.3 Product Milestone 11
3.2.4 Custom NX 60Clinical Trials 1 12
3.2.5 Custom NX 60Clinical Trials 2 13
3.2.6 Custom NX 60Clinical Trials 3 13
3.2.7 Product Patent Details 14
3.3 Custom Bare Metal Stent System 17
3.3.1 Product Status 17
3.3.2 Product Description 17
3.3.3 Clinical Trials 17
3.3.4 Product Patent Details 18
3.4 Custom NX 36 Drug eluting stent 18
3.4.1 Product Status 18
3.4.2 Product Description 19
3.4.3 Product Milestone 19
3.4.4 Custom NX 36 Drug eluting stentClinical Trials 1 20
3.4.5 Custom NX 36 Drug eluting stentClinical Trials 2 20
3.4.6 Custom NX 36 Drug eluting stentClinical Trials 3 21
3.4.7 Custom NX 36 Drug eluting stentClinical Trials 4 21
3.4.8 Custom NX 36 Drug eluting stentClinical Trials 5 21
3.4.9 Product Patent Details 22
3.5 Nitinol Self expanding peripheral artery stent 24
3.5.1 Product Status 24
3.5.2 Product Description 24
3.5.3 Product Patent Details 25
3.6 Bioabsorbable Stent System 25
3.6.1 Product Status 25
3.6.2 Product Description 25
3.6.3 Product Patent Details 26
3.7 Quick Deployment Handles 26
3.7.1 Product Status 26
3.7.2 Product Description 26
4 Recent Developments 27
4.1 Product News 27
4.1.1 Oct 13, 2008: Custom NX Drug Eluting Stent System Continues To Demonstrate Favorable Outcomes In Challenging Patient Populations At One, Two And Three Years 27
4.1.2 Oct 10, 2008: XTENT Announces Clinical Trial Data To Be Presented At Annual Meeting Of Transcatheter Cardiovascular Therapeutics Next Week 27
4.1.3 Aug 26, 2008: Xtent Inc Announces CUSTOM II Data Selected For Publication In EuroIntervention 27
4.1.4 Jun 23, 2008: XTENT Announces European Regulatory Update 28
4.1.5 May 13, 2008: XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented At EuroPCR Meeting 28
4.1.6 Dec 27, 2007: XTENT Submits CE Mark Registration To Market Custom NX Drug-Eluting Stent System In Europe 28
4.1.7 Oct 22, 2007: XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data For Novel Drug-Eluting Stent System 29
4.1.8 May 22, 2007: XTENT Announces Promising Six-Month Custom II Trial Data Presented At EuroPCR Meeting 29
4.1.9 May 16, 2006: Xtent CUSTOM I Trial Shows Zero Restenosis, Favorable Late Loss Results At Eight Months 30
4.2 Clinical Trials 30
4.2.1 Oct 13, 2008: Custom NX Drug Eluting Stent System Continues To Demonstrate Favorable Outcomes In Challenging Patient Populations At One, Two And Three Years 30
4.2.2 Oct 10, 2008: XTENT Announces Clinical Trial Data To Be Presented At Annual Meeting Of Transcatheter Cardiovascular Therapeutics Next Week 30
4.2.3 Aug 26, 2008: Xtent Inc Announces CUSTOM II Data Selected For Publication In EuroIntervention 30
4.2.4 May 13, 2008: XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented At EuroPCR Meeting 31
4.2.5 Oct 22, 2007: XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data For Novel Drug-Eluting Stent System 31
4.2.6 May 22, 2007: XTENT Announces Promising Six-Month Custom II Trial Data Presented At EuroPCR Meeting 32
4.2.7 May 16, 2006: Xtent CUSTOM I Trial Shows Zero Restenosis, Favorable Late Loss Results At Eight Months 32
5 Appendix 33
5.1 Methodology 33
5.1.1 Coverage 33
5.1.2 Secondary Research 34
5.1.3 Primary Research 34
5.1.4 Expert Panel Validation 35
5.2 Contact Us 35
5.3 About us35
5.4 Disclaimer 35

Executive Summary

1.2 List of Figures
Figure 1: XTENT, Inc. Pipeline Products By News Summary 10
Figure 2: Global Markets Direct Methodology 33


Companies Mentioned The following companies are the major competitors of XTENT, Inc.: Biosensors International Group, Ltd. Boston Scientific Corporation Cook Group Incorporated Johnson & Johnson


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/605367

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 29/11/2009 00:38:06
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
XTENT, Inc. Product Pipeline Analysis
Web Address:
http://www.researchandmarkets.com/reports/605367
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €504.00
Electronic (PDF) - Site License €1,007.00
Electronic (PDF) - Enterprisewide €1,511.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 29/11/2009 00:38:06

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)